Home
    Disclaimer
    Fosazepam molecular structure

    Fosazepam Stats & Data

    NPS DataHub
    MW360.78
    FormulaC18H18ClN2O2P
    CAS35322-07-7
    IUPAC7-chloro-1-(dimethylphosphorylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
    SMILESClc1ccc2N(CP(C)(C)=O)C(=O)CN=C(c3ccccc3)c2c1
    InChIKeyJMYCGCXYZZHWMO-UHFFFAOYSA-N
    Chemical Class Benzodiazepine
    Psychoactive Class Depressant
    Half-Life Unknown for parent drug; if converted to nordazepam (as reported by community sources), effective half‑life may be prolonged (nordazepam often cited at 50–120 h).

    Effect Profile

    Curated
    Benzodiazepine 7.1

    Strong euphoria with moderate anxiolysis and sedation, mild cognitive impairment

    Anxiolysis×3
    7
    Sedation / Relaxation×2
    7
    Motor / Cognitive Impairment×1
    5
    Euphoria / Mood Lift×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown for parent drug; if converted to nordazepam (as reported by community sources), effective half‑life may be prolonged (nordazepam often cited at 50–120 h).
    Addiction Potential
    Moderate to high, consistent with other benzodiazepines; risk of tolerance, dependence, and protracted withdrawal escalates with frequent use and redosing.

    Tolerance Decay

    Full tolerance 14d Half tolerance 14d Baseline ~56d

    Benzodiazepine tolerance can develop within 1–4 weeks of frequent/daily use and decays over weeks to months after cessation. Cross‑tolerance within the benzodiazepine class is substantial; partial cross‑tolerance with Z‑drugs is expected. Data are based on class-level observations and anecdotal reports rather than fosazepam-specific studies.

    Cross-Tolerances

    Other benzodiazepines
    100% ●●○
    Z-drugs (zolpidem, zopiclone)
    70% ●○○

    Harm Reduction

    drugs.wiki

    Fosazepam is described as a diazepam-derived benzodiazepine; specific peer‑reviewed pharmacokinetic data are sparse, so potency and duration should be considered uncertain—start low and avoid stacking doses. Some community sources discuss fosazepam as a water‑soluble prodrug that is converted in vivo to long‑acting metabolites (e.g., nordazepam), which could prolong impairment into the next day; treat this as plausible but not confirmed by primary literature. Combining benzodiazepines with other CNS depressants—especially opioids, alcohol, barbiturates, or GHB/GBL—markedly increases risk of respiratory depression, aspiration, and fatal overdose. Even in the absence of other depressants, benzodiazepines can cause anterograde amnesia, motor incoordination, and disinhibition; avoid driving and high‑risk tasks until fully recovered. Blackouts and risky behaviors are more likely at higher doses or with redosing; set dose limits in advance and have a trusted sober person hold the supply if impulse control is an issue. Tolerance develops with repeated use over days to weeks; spacing sessions by multiple weeks materially reduces cumulative risk. If daily use occurs, do not abruptly stop—taper gradually under medical supervision to avoid seizures and other severe withdrawal phenomena. Never inject tablets or powders: fillers and insoluble particles can cause serious tissue damage and emboli; water solubility does not make pill solutions safe for IV use. If you must prepare solutions for accurate dosing, use clean volumetric techniques, label concentrations, and store securely to prevent accidental ingestion. People with respiratory disease, sleep apnea, or concurrent opioid therapy face elevated risks from any benzodiazepine; extra caution and avoidance of combinations are prudent. Grapefruit juice and other CYP inhibitors can raise levels of some benzodiazepines; fosazepam’s exact metabolic route is unclear, so avoid strong inhibitors/inducers unless advised by a clinician. Use drug‑interaction charts and equivalence calculators only as rough guides; interindividual response varies widely.

    ← Back to Fosazepam